With emerging evidence for the prognostic and potential predictive value of immunotherapy, chemoimmunotherapy, and antiangiogenic therapy, the addition of TP53 mutation testing in patients with KRASmut NSCLC may be warranted. Here, TP53 is linked to non-small cell lung carcinoma.